Drug intelligence / Profile preview

WS012

Development stage: Unknown
Lead developer: Waterstone Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

WS012 is a small molecule drug developed by Waterstone Pharmaceuticals for the treatment of hyperlipidemia and primary sclerosing cholangitis. It functions by modulating bile acid metabolism, likely acting as a Farnesoid X receptor (FXR) agonist. Clinical evaluations have focused on its ability to reduce total bile acid (TBA) levels in serum and feces, as well as its impact on lipid profiles, including triglycerides, total cholesterol, and LDL-C. The drug has completed Phase 1 safety and pharmacodynamic studies in healthy subjects and is currently in Phase 2 development for hyperlipidemia.

Targets

FXR (Farnesoid x-activated receptor)

Beyond the preview

Go deeper on WS012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WS012.

Explore the full profile